As observers eagerly await its listing on the US NASDAQ tomorrow (5 May), Acelyrin, Inc. has significantly upped the size of its initial public offering ahead of entry into the hot market of hidradenitis suppurativa (HS) and other lucrative immunology indications.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?